Inhibrx, Inc. - 29 May 2024 Form 4 Insider Report for Inhibrx Biosciences, Inc. (INBX)

Role
10%+ Owner
Signature
/s/ Martin Travers, Authorized Signatory on behalf of Inhibrx, Inc.
Issuer symbol
INBX
Transactions as of
29 May 2024
Net transactions value
$0
Form type
4
Filing time
31 May 2024, 16:30:04 UTC
Previous filing
24 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INBX Common Stock, par value $0.0001 per share Other -13,316,140 -92% 1,157,926 29 May 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Inhibrx, Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On January 8, 2024, Inhibrx, Inc. ("RemainCo"), acquired 100 shares, par value $0.0001 per share (the "Common Stock"), of Inhibrx Biosciences, Inc. (the "Issuer"), which at the time constituted all of the issued and outstanding Common Stock of the Issuer. On May 29, 2024, the Common Stock was split, resulting in RemainCo's ownership of an aggregate 14,474,066 shares of Common Stock of the Issuer.
F2 On May 29, 2024 at 11:59 p.m., New York City time, RemainCo distributed approximately 92% of the Common Stock of the Issuer to the holders of record of RemainCo as of May 17, 2024.